摘要
Abstract
Objective:To investigate the clinical efficacy and safety of Edaravone combined with Urinary Kallidinogenase in the treatment of patients with acute cerebral infarction(ACI).Methods:Data of 92 patients with ACI admitted to Ningjin County Hospital of Traditional Chinese Medicine from January 2023 to July 2024 were retrospectively analyzed,and they were divided into a combination group and a control group with 46 cases in each group according to different treatment methods.The control group was treated with Edaravone,the combination group combined with Urinary Kallidinogenase on the basis of the control group.Both groups were treated for 14 days.The degree of neurological impairment,the level of Lipoprotein-associated phospholipase A2(Lp-PLA2)and vascular endothelial growth factor(VEGF),clinical efficacy and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,the Chinese Stroke Scale score of the combined group was lower than that of the control group,the difference was statistically significant(P<0.05).After treatment,the level of Lp-PLA2 in the combination group was lower than that in control group,and the level of VEGF was higher than that in control group,with statistical significance(P<0.05).The total effective rate of the combined group was 97.83%,which was higher than 80.42%of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the combined group was 4.35%,compared with 10.87%in the control group,with no statistical significance(P>0.05).Conclusion:Edaravone combined with Urinary Kallidinogenase in the treatment of patients with ACI can reduce the degree of neurological impairment,reduce the level of inflammatory markers and cytokines,and has good clinical therapeutic effect and drug safety.关键词
急性脑梗死/依达拉奉/尤瑞克林/神经功能/血管内皮细胞Key words
Acute cerebral infarction/Edaravone/Urinary Kallidinogenase/Nerve function/Vascular endothelial cell分类
医药卫生
